Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The two major classes of antidiabetic drugs, sulfonylureas and metformin, may differentially affect macrovascular complications and mortality in diabetic patients. We compared the long-term effects of glipizide and metformin on the major cardiovascular events in type 2 diabetic patients who had a history of coronary artery disease (CAD). RESEARCH DESIGN AND METHODS: This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. A total of 304 type 2 diabetic patients with CAD, mean age = 63.3 years (range, 36–80 years), were enrolled. Participants were randomly assigned to receive either glipizide (30 mg daily) or metformin (1.5 g daily) for 3 years. The primary end points were times to the composite of recurrent cardiovascular events, including death from a cardiovascular cause, death from any cause, nonfatal myocardial infarction, nonfatal stroke, or arterial revascularization. RESULTS: At the end of study drug administration, both groups achieved a significant decrease in the level of glycated hemoglobin (7.1% in the glipizide group and 7.0% in the metformin group). At a median follow-up of 5.0 years, 91 participants had developed 103 primary end points. Intention-to-treat analysis showed an adjusted hazard ratio (HR) of 0.54 (95% CI 0.30–0.90; P = 0.026) for the composites of cardiovascular events among the patients that received metformin, compared with glipizide. The secondary end points and adverse events were not significantly different between the two groups. CONCLUSIONS: Treatment with metformin for 3 years substantially reduced major cardiovascular events in a median follow-up of 5.0 years compared with glipizide. Our results indicated a potential benefit of metformin therapy on cardiovascular outcomes in high-risk patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Follow-up studies involving metformin appeared to support a potential cardiovascular benefit, but these studies were small and the findings were not robust.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [207]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Cited by
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536
(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.010 · Cited by 1,896
Metformin: from mechanisms of action to therapies
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.009 · Cited by 1,193
Standards of medical care for type 2 diabetes in China 2019
Jia, W., Weng, J., Zhu, D., Ji, L., Lu, J., Zhou, Z., Zou, D., Guo, L., Ji, Q., Chen, L., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3158 · Cited by 700
“In China, randomized controlled clinical trials have been conducted to investigate the effect of metformin and sulfonylureas on recurrent cardiovascular events in patients with T2DM combined with coronary heart disease, and the results showed that metformin treatment was correlated with a significant reduction of majo…”
BackgroundSelf-citationPalmer, S. C., Tendal, B., Mustafa, R. A., Vandvik, P. O., Li, S., Hao, Q., Tunnicliffe, D., Ruospo, M., Natale, P., Saglimbene, V., et al. (2021) · BMJ · doi:10.1136/bmj.m4573 · Cited by 679
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
“Only 1 RCT specified a cardiovascular outcome as a primary outcome (15).”
BackgroundResultInfluentialEpigenetic regulation of aging: implications for interventions of aging and diseases
Wang, K., Liu, H., Hu, Q., Wang, L., Liu, J., Zheng, Z., Zhang, W., Ren, J., Zhu, F., & Liu, G.-H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01211-8 · Cited by 663
Kenny, H. C., & Abel, E. D. (2019) · Circulation Research · doi:10.1161/circresaha.118.311371 · Cited by 660
JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome
Kimura, K., Kimura, T., Ishihara, M., Nakagawa, Y., Nakao, K., Miyauchi, K., Sakamoto, T., Tsujita, K., Hagiwara, N., Miyazaki, S., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0133 · Cited by 565
The Warburg effect then and now: From cancer to inflammatory diseases
Palsson‐McDermott, E. M., & O'Neill, L. A. J. (2013) · BioEssays · doi:10.1002/bies.201300084 · Cited by 537
“However, metformin also confers benefits that include a reduction in the risk of myocardial infarction, stroke, lower cancer mortality, as well as attenuating airway inflammation [65–68].”
BackgroundFox, C. S., Golden, S. H., Anderson, C., Bray, G. A., Burke, L. E., de Boer, I. H., Deedwania, P., Eckel, R. H., Ershow, A. G., Fradkin, J., et al. (2015) · Diabetes Care · doi:10.2337/dci15-0012 · Cited by 492
“and coronary artery disease (CAD) who received metformin compared with glipizide (152).”
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Ma, C.-X., Ma, X.-N., Guan, C.-H., Li, Y.-D., Mauricio, D., & Fu, S.-B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01516-6 · Cited by 464
“However, there is insufficient evidence for the use of metformin for secondary prevention in patients with T2DM and established CVD [47].”
BackgroundMetformin and inflammation: its potential Beyond glucose-lowering effect
Saisho, Y. (2015) · Endocrine, Metabolic & Immune Disorders-Drug Targets · doi:10.2174/1871530315666150316124019 · Cited by 450
Qaseem, A., Humphrey, L. L., Sweet, D. E., Starkey, M., Shekelle, P., & for the Clinical Guidelines Committee of the American College of Physicians* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-3-201202070-00011 · Cited by 400
Type-2 diabetes mellitus and cardiovascular disease
Henning, R. J. (2018) · Future Cardiology · doi:10.2217/fca-2018-0045 · Cited by 398
Fox, C. S., Golden, S. H., Anderson, C., Bray, G. A., Burke, L. E., de Boer, I. H., Deedwania, P., Eckel, R. H., Ershow, A. G., Fradkin, J., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000230 · Cited by 386
“026) for a composite CVD outcome in patients with type 2 diabetes mellitus and coronary artery disease (CAD) who received metformin compared with glipizide.(152) Beyond metformin, there are limited data on the comparative effectiveness of the many other effective antihyperglycemic drugs; most studies are of short dura…”
Wang, Q., Zhang, M., Torres, G., Wu, S., Ouyang, C., Xie, Z., & Zou, M.-H. (2017) · Diabetes · doi:10.2337/db16-0915 · Cited by 370
“In addition to lowering blood glucose, metformin reduces cardiovascular complications in patients with diabetes (16).”
BackgroundBannister, C. A., Holden, S. E., Jenkins‐Jones, S., Morgan, C. L., Halcox, J. P., Schernthaner, G., Mukherjee, J., & Currie, C. J. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12354 · Cited by 356
“A relative benefit of metformin has also been reported in various observational studies [21,30–34], including decreased risk of cancer [35–38].”
BackgroundHan, Y., Xie, H., Liu, Y., Gao, P., Yang, X., & Shen, Z. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0900-7 · Cited by 337
García-Sánchez, A., Miranda-Díaz, A. G., & Cardona-Muñoz, E. G. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/2082145 · Cited by 331
“In addition to reducing blood glucose, metformin reduces cardiovascular complications in patients with DM, prevents the progression of the thickness of the intima media of the common carotid, and reduces the incidence of myocardial infarction in patients with type 2 DM [85, 86].”
BackgroundMetformin: a review of its potential indications
Wang, Y.-W., He, S.-J., Feng, X., Cheng, J., Luo, Y.-T., Tian, L., & Huang, Q. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s141675 · Cited by 320
“2 g; Table 1) substantially reduced major cardiovascular events in a median follow-up of 5 years, which indicated a potential benefit of metformin treatment on cardiovascular outcomes in high-risk patients.(10) After all, metformin is the only antidiabetic drug to be recommended by the 2013 AACE guidelines for cardiov…”
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 258
Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes
Dutta, S., Shah, R. B., Singhal, S., Dutta, S. B., Bansal, S., Sinha, S., & Haque, M. (2023) · Drug Design, Development and Therapy · doi:10.2147/dddt.s409373 · Cited by 248
Cardiovascular safety of sulfonylureas: a meta‐analysis of randomized clinical trials
Monami, M., Genovese, S., & Mannucci, E. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12116 · Cited by 251
“Thus, the meta-analysis is largely driven by the ADOPT trial [22], which reported a trend in favour of sulfonylureas for cardiovascular events, and by a more recent study showing the superiority of metformin over glipizide in patients with prior events [14].”
BackgroundResultPharmacologic Glycemic Management of Type 2 Diabetes in Adults
Lipscombe, L., Booth, G., Butalia, S., Dasgupta, K., Eurich, D. T., Goldenberg, R., Khan, N., MacCallum, L., Shah, B. R., & Simpson, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.034 · Cited by 246
“Compared to sulfonylureas, metformin monotherapy has comparable A1C-lowering effects, but better glycemic durability (18), a lower risk of hypoglycemia (19), less weight gain (19,20) and lower CV risk (20).”
The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk
Caussy, C., Aubin, A., & Loomba, R. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01383-7 · Cited by 230
Comparative review of dipeptidyl peptidase‐4 inhibitors and sulphonylureas
Deacon, C. F., & Lebovitz, H. E. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12610 · Cited by 213
“Similar conclusions were drawn from a small, probably under-powered, prospective study comparing 3 years treatment with metformin and glipizide over a follow-up period of 5 years [107].”
ResultCardiovascular disease in diabetes, beyond glucose
Eckel, R. H., Bornfeldt, K. E., & Goldberg, I. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.07.001 · Cited by 212
Nesti, L., & Natali, A. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.04.009 · Cited by 211
Qaseem, A., Barry, M. J., Humphrey, L. L., Forciea, M. A., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m16-1860 · Cited by 207
Diabetes in China: a societal solution for a personal challenge
Chan, J. C. N., Zhang, Y., & Ning, G. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70144-5 · Cited by 200
Self-citationZhao, J., Fan, H., Wang, T., Yu, B., Mao, S., Wang, X., Zhang, W., Wang, L., Zhang, Y., Ren, Z., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01548-y · Cited by 190
“Clinical studies have confirmed that metformin can significantly reduce cardiovascular events in patients with IR, which also supports the important role of IR in NAFLD patients with CHD [34].”
BackgroundSelf-citationShould metformin remain the first-line therapy for treatment of type 2 diabetes?
Baker, C., Retzik-Stahr, C., Singh, V., Plomondon, R., Anderson, V., & Rasouli, N. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820980225 · Cited by 181
Metformin: A Hopeful Promise in Aging Research
Novelle, M. G., Ali, A., Diéguez, C., Bernier, M., & de Cabo, R. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025932 · Cited by 178
“There is some evidence that metformin may also have cardioprotective effects (Eurich et al. 2013; Hong et al. 2013) and contribute to the prevention of some forms of human cancer (Cazzaniga et al.”
BackgroundScheen, A. J., & Paquot, N. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.02.006 · Cited by 174
“No difference was observed between the two groups regarding all-cause mortality, but the study had no sufficient statistical power to detect specifically such a difference[24].”
Lazarus, B., Wu, A., Shin, J.-I., Sang, Y., Alexander, G. C., Secora, A., Inker, L. A., Coresh, J., Chang, A. R., & Grams, M. E. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.0292 · Cited by 167
Luo, F., Das, A., Chen, J., Wu, P., Li, X., & Fang, Z. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0860-y · Cited by 163
The Current and Potential Therapeutic Use of Metformin—The Good Old Drug
Drzewoski, J., & Hanefeld, M. (2021) · Pharmaceuticals · doi:10.3390/ph14020122 · Cited by 193
“Metformin has also been shown to be effective in secondary prevention of cardiovascular outcomes [3,4].”
BackgroundMone, P., Lombardi, A., Gambardella, J., Pansini, A., Macina, G., Morgante, M., Frullone, S., & Santulli, G. (2022) · Diabetes Care · doi:10.2337/dc21-2434 · Cited by 151
Metformin and other antidiabetic agents in renal failure patients
Lalau, J., Arnouts, P., Sharif, A., & Broe, M. E. D. (2014) · Kidney International · doi:10.1038/ki.2014.19 · Cited by 159
Rados, D. V., Pinto, L. C., Remonti, L. R., Leitão, C. B., & Gross, J. L. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001992 · Cited by 143
Goldberg, R. B., Aroda, V. R., Bluemke, D. A., Barrett-Connor, E., Budoff, M., Crandall, J. P., Dabelea, D., Horton, E. S., Mather, K. J., Orchard, T. J., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.025483 · Cited by 137
“sulfonylurea treatments (19) and versus placebo in insulin treated subjects with type 2 diabetes”
BackgroundMetformin: A Novel Weapon Against Inflammation
Bai, B., & Chen, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.622262 · Cited by 161
Kwan, T. W., Wong, S. S., Hong, Y., Kanaya, A. M., Khan, S. S., Hayman, L. L., Shah, S. H., Welty, F. K., Deedwania, P. C., Khaliq, A., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001145 · Cited by 133
Kulkarni, A. S., Aleksić, S., Berger, D. M., Sierra, F., Kuchel, G. A., & Barzilai, N. (2022) · Aging Cell · doi:10.1111/acel.13596 · Cited by 137
“UK Prospective Diabetes Study (UKPDS) Group,” 1998; Hong et al., 2013; Knowler et al., 2002).”
BackgroundInfluentialWu, Z., Jin, C., Vaidya, A., Jin, W., Huang, Z., Wu, S., & Gao, X. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07381 · Cited by 121
“These behaviors may favorably modify BP. Finally, we did not collect information on specific causes of death.”
ResultInfluentialRobichaud, S., Rasheed, A., Pietrangelo, A., Kim, A. D., Boucher, D. M., Emerton, C., Vijithakumar, V., Gharibeh, L., Fairman, G., Mak, E., et al. (2022) · Circulation Research · doi:10.1161/circresaha.121.320047 · Cited by 127
New insights into insulin action and resistance in the vasculature
Manrique, C. M., Lastra, G., & Sowers, J. R. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12395 · Cited by 132
Metformin: Therapeutic profile in the treatment of type 2 diabetes
Bailey, C. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15663 · Cited by 171
“117 Also, a study in insulin-treated T2D noted a 39% reduction in macro-vascular morbidity and mortality after the addition of metformin for 4.3 years.”
InfluentialBu, Y., Peng, M., Tang, X., Xu, X., Wu, Y., Chen, A. F., & Yang, X. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17519 · Cited by 127
The beneficial roles of metformin on the brain with cerebral ischaemia/reperfusion injury
Leech, T., Chattipakorn, N., & Chattipakorn, S. C. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104261 · Cited by 114
Chinese Guideline on the Primary Prevention of Cardiovascular Diseases
Chinese Society of Cardiology of Chinese Medical Association, C. D. P. A. R. C. O. C. A. O. R. M. (2021) · Cardiology Discovery · doi:10.1097/cd9.0000000000000025 · Cited by 132
Therapeutic Manipulation of Myocardial Metabolism
Honka, H., Solis‐Herrera, C., Triplitt, C. L., Norton, L., Butler, J., & DeFronzo, R. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.057 · Cited by 108
Hemmingsen, B., Schroll, J. B., Wetterslev, J., Gluud, C., Vaag, A., Sonne, D. P., Lundstrom, L. H., & Almdal, T. (2014) · CMAJ Open · doi:10.9778/cmajo.20130073 · Cited by 96
Challenges in developing Geroscience trials
Rolland, Y., Sierra, F., Ferrucci, L., Barzilai, N., De Cabo, R., Mannick, J., Oliva, A., Evans, W., Angioni, D., De Souto Barreto, P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39786-7 · Cited by 91
Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
Lim, L.-L., Chow, E., & Chan, J. C. N. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00776-2 · Cited by 91
Mechanisms of action of metformin with special reference to cardiovascular protection
Zilov, A. V., Abdelaziz, S. I., Alshammary, A., Zahrani, A. A., Amir, A., Khalil, S. H. A., Brand, K. M. G., Elkafrawy, N., Hassoun, A. A. K., Jahed, S. A., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3173 · Cited by 94
“Here, the other compared metformin with glipizide on patients with type 2 diabetes and coronary artery disease.(53) Many observational studies have also reported cardiovascular benefits of metformin, and these have been reviewed elsewhere.”
ResultMetformin: An old drug against old age and associated morbidities
Salvatore, T., Pafundi, P. C., Morgillo, F., Liello, R. D., Galiero, R., Nevola, R., Marfella, R., Monaco, L., Rinaldi, L., Adinolfi, L. E., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108025 · Cited by 91
Bell, S., Farran, B., McGurnaghan, S., McCrimmon, R. J., Leese, G. P., Petrie, J. R., McKeigue, P., Sattar, N., Wild, S., McKnight, J., et al. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0579-5 · Cited by 84
Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study
Du, Y., Zhu, Y., Zhou, Y., Ding, J., & Liu, J. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00108-w · Cited by 96
Translating the Science of Aging into Therapeutic Interventions
Kirkland, J. L. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025908 · Cited by 78
“Several of these agents also appear to delay cancers, cognitive decline, cardiac dysfunction, and other agerelated diseases and disabilities in several species, including humans (Chiasson et al. 2002; Zeymer et al. 2004; Basso et al. 2005; Dykens et al. 2005; Johnson et al. 2005; Crandall et al. 2006; Hanon et al. 200…”
BackgroundDifferential epigenetic factors in the prediction of cardiovascular risk in diabetic patients
Napoli, C., Benincasa, G., Schiano, C., & Salvatore, M. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz062 · Cited by 84
Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer
Abdelmoneim, A. S., Eurich, D. T., Light, P. E., Senior, P. A., Seubert, J. M., Makowsky, M. J., & Simpson, S. H. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12456 · Cited by 78
“Since the publication of the UGDP, only one long-term clinical trial specifically designed to assess cardiovascular outcomes in people randomized to sulphonylureas has been published [38].”
BackgroundInsulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications
Abdul‐Ghani, M. A., Jayyousi, A., DeFronzo, R. A., Asaad, N., & Suwaidi, J. M. S. A. (2017) · Current Vascular Pharmacology · doi:10.2174/1570161115666171010115119 · Cited by 81
Liu, R., Wang, H., Xu, B., Chen, W., Turlova, E., Dong, N., Sun, C. L. F., Lu, Y., Fu, H., Shi, R., et al. (2016) · Diabetes · doi:10.2337/db15-1737 · Cited by 82
Morgan, C. L., Mukherjee, J., Jenkins‐Jones, S., Holden, S. E., & Currie, C. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12306 · Cited by 86
Maniar, K., Moideen, A., Mittal, A., Patil, A., Chakrabarti, A., & Banerjee, D. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.003 · Cited by 77
Cardiovascular Protection in People With Diabetes
Stone, J. A., Houlden, R. L., Lin, P., Udell, J. A., & Verma, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.024 · Cited by 83
Kanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · UCL Discovery (University College London) · Cited by 71
Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2
Maranta, F., Cianfanelli, L., & Cianflone, D. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_514 · Cited by 90
Schernthaner, G., Brand, K. M. G., & Bailey, C. J. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155160 · Cited by 77
Berkowitz, S. A., Krumme, A. A., Avorn, J., Brennan, T., Matlin, O. S., Spettell, C. M., Pezalla, E. J., Brill, G., Shrank, W. H., & Choudhry, N. K. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.5294 · Cited by 68
Cardiovascular safety of anti-diabetic drugs
Kumar, R. B., Kerins, D. M., & Walther, T. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv035 · Cited by 72
Autophagy Modulators in Cancer Therapy
Buzun, K., Gornowicz, A., Lesyk, R., Bielawski, K., & Bielawska, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115804 · Cited by 70
Rosenblit, P. D. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0412-7 · Cited by 75
“The Study on the Prognosis and Effect of Antidiabetic Drugs on Type 2 Diabetes Mellitus with Coronary Artery Disease (SPREAD-DIMCAD) reported that 3 years of metformin treatment was associated with significantly lower CVD risk after an additional 2 years of post-drug followup compared to glipizide in 304 patients with…”
ResultMetformin monotherapy for adults with type 2 diabetes mellitus
Gnesin, F., Thuesen, A. C. B., Kähler, L. K. A., Madsbad, S., & Hemmingsen, B. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012906.pub2 · Cited by 62
Zhang, K., Wang, T., Sun, G., Xiao, J.-X., Jiang, L., Tou, F., Qu, X.-H., & Han, X. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.05.019 · Cited by 67
Messaoudi, S. E., Nederlof, R., Zuurbier, C. J., van Swieten, H. A., Pickkers, P., Noyez, L., Dieker, H.-J., Coenen, M. J. H., Donders, A. R. T., Vos, A., et al. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00121-7 · Cited by 60
Kanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W. W. S., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013650.pub2 · Cited by 111
Cardiovascular safety profile of currently available diabetic drugs.
Azimova, K., Juan, Z. T. S., & Mukherjee, D. (2014) · PubMed · Cited by 78
Unraveling the role of ER stress inhibitors in the context of metabolic diseases
Sarvani, C., Sireesh, D., & Ramkumar, K. M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.018 · Cited by 66
Type 2 diabetes and cardiovascular disease: what next?
Joseph, J. J., & Golden, S. H. (2014) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000044 · Cited by 57
“In a study of 304 Chinese T2DM patients with a history of coronary artery disease (CAD), individuals treated with metformin as compared with glipizide for 3 years had a 46% decrease in cardiovascular events [13].”
BackgroundZou, R., Nie, C., Pan, S., Wang, B., Hong, X., Xi, S., Bai, J., Yu, M., Liu, J., & Yang, W. P. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.03.010 · Cited by 56
Chen, Y., Shen, Y.-C., Lai, Y., Wang, C.-Y., Lin, K., Feng, S.-C., Liang, C.-Y., Wei, L.-C., & Chou, P. (2019) · Journal of Ophthalmology · doi:10.1155/2019/1649156 · Cited by 60
Seneviratne, A. N., Cave, L., Hyde, G. D., Moestrup, S. K., Carling, D., Mason, J. C., Haskard, D. O., & Boyle, J. J. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa171 · Cited by 61
Diabetes mellitus type 2 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Sukhareva, O. Y., Galstyan, G. R., Tokmakova, A. Y., Nikonova, T. V., Surkova, E. V., Кононенко, И. В., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12507 · Cited by 69
Dissecting the Mechanisms Underlying Unusually Successful Human Health Span and Life SpanPreprint
Milman, S., & Barzilai, N. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025098 · Cited by 55
“This finding has been validated and reproduced by other studies and meta-analysis (Johnson et al. 2005; Lamanna et al. 2011; Roumie et al. 2012; Hong et al. 2013; Whittington et al. 2013).”
Lee, G., Oh, S.-W., Hwang, S.-S., Yoon, J. W., Kang, S., Joh, H.-K., Kwon, H., Kim, J., & Park, D. (2017) · PLOS ONE · doi:10.1371/journal.pone.0177646 · Cited by 53
“Maruthur and colleagues concluded that metformin is associated with a lower risk of cardiovascular mortality than sul-fonylureas [28] [29,30] and several observational studies.”
Metformin: an old therapy that deserves a new indication for the treatment of obesity.
Igel, L. I., Sinha, A., Saunders, K. H., Apovian, C. M., Vojta, D., & Aronne, L. J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0568-3 · Cited by 52
Repurposing Antidiabetic Drugs for Cardiovascular Disease
Schubert, M., Hansen, S., Leefmann, J., & Guan, K. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.568632 · Cited by 61
Ussher, J. R., Greenwell, A. A., Nguyen, M.-A., & Mulvihill, E. E. (2022) · Diabetes · doi:10.2337/dbi20-0049 · Cited by 50
“The Study on the Prognosis and Effect of Antidiabetic Drugs on Type 2 Diabetes Mellitus with Coronary Artery Disease (SPREAD-DIMCAD) indicated that metformin substantially reduced MACE compared with glipizide, despite similar HbA1c levels (68), suggesting that metformin’s effects are independent of its glucose-lowerin…”
BackgroundWhere Does Metformin Stand in Modern Day Management of Type 2 Diabetes?
Ahmad, E., Sargeant, J. A., Zaccardi, F., Khunti, K., Webb, D. R., & Davies, M. J. (2020) · Pharmaceuticals · doi:10.3390/ph13120427 · Cited by 59
Monami, M., Candido, R., Pintaudi, B., Targher, G., Mannucci, E., Mannucci, E., Candido, R., Pintaudi, B., Targher, G., Monache, L. D., et al. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.11.031 · Cited by 50
Top, W. M. C., Kooy, A., & Stehouwer, C. D. A. (2022) · Pharmaceuticals · doi:10.3390/ph15030312 · Cited by 54
“They published an updated meta-analysis in 2021 in which they only selected the UKPDS and the SPREAD-DIMCAD for their endpoint on major cardiovascular effects with a combined odds ratio of 0.52 (95% CI 0.37, 0.73) favoring metformin and a nonsignificant trend for reduced all-cause mortality (odds ratio (OR) 0.80 (95%…”
BackgroundMethodInfluentialNovel epigenetic-sensitive clinical challenges both in type 1 and type 2 diabetes
Sommese, L., Benincasa, G., Lanza, M., Sorriento, A., Schiano, C., Lucchese, R., Alfano, R., Nicoletti, G. F., & Napoli, C. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.08.012 · Cited by 52
Metadata
- Authors
- Hong, J., Zhang, Y., Lai, S., Lv, A., Su, Q., Dong, Y., Zhou, Z., Tang, W., Zhao, J., Cui, L., Zou, D., Wang, D., Li, H., Liu, C., Wu, G., Shen, J., Zhu, D., Wang, W., Shen, W., Ning, G., & on behalf of the SPREAD-DIMCAD Investigators
- Affiliations
- Shanghai Jiao Tong University (CN)
- Johns Hopkins University (US)
- Second Xiangya Hospital of Central South University (CN)
- Shandong University (CN)
- Second Military Medical University (CN)
- The First Affiliated Hospital of Wenzhou Medical College, Zhejiang Province, China
- Sir Run Run Shaw Hospital (CN)
- Jiangsu Province Hospital (CN)
- Shanghai Ten’s People’s Hospital of Tongji University, Shanghai, China
- Nanfang Hospital (CN)
- Nanjing Drum Tower Hospital (CN)
- Corresponding author
- Ning, Guang
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-04-13
- Volume
- 36
- Issue
- 5
- Pages
- 1304-1311
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3631843
- OpenAlex
- W2141199290
- Cited by
- 366
- References
- 37
- Citations by year
- 2026: 7 · 2025: 16 · 2024: 20 · 2023: 26 · 2022: 43 · 2021: 35 · 2020: 44 · 2019: 31 · 2018: 31 · 2017: 28 · 2016: 30 · 2015: 20 · 2014: 22 · 2013: 12
- FWCI
- 14.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81170784, 1994DP131044, 201002002, 2012ZX09303006-001, 30971077)
- Shanghai Municipal Education Commission
- National Key New Drug Creation and Manufacturing Program, Ministry of Science and Technology (2012ZX09303006‐001)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- metformin, glipizide, type 2 diabetes, coronary artery disease, cardiovascular outcomes, sulfonylureas, myocardial infarction, stroke, cardiovascular mortality, HbA1c, macrovascular complications
- MeSH terms
- Adult, Aged, Aged, 80 and over, Coronary Artery Disease, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glipizide, Humans, Male, Metformin, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.